The lipolytic processing of triglyceride-rich lipoproteins by lipoprotein lipase (LPL) is the central event in plasma lipid metabolism, providing lipids for storage in adipose tissue and fuel for vital organs such as the heart. LPL is synthesized and secreted by myocytes and adipocytes, but then finds its way into the lumen of capillaries, where it hydrolyzes lipoprotein triglycerides. The mechanism by which LPL reaches the lumen of capillaries has remained an unresolved problem of plasma lipid metabolism. Here, we show that GPIHBP1 is responsible for the transport of LPL into capillaries. In Gpihbp1-deficient mice, LPL is mislocalized to the interstitial spaces surrounding myocytes and adipocytes. Also, we show that GPIHBP1 is located at the basolateral surface of capillary endothelial cells and actively transports LPL across endothelial cells. Our experiments define the function of GPIHBP1 in triglyceride metabolism and provide a mechanism for the transport of LPL into capillaries.
INTRODUCTION
The lipolytic processing of triglyceride-rich lipoproteins by lipoprotein lipase (LPL) provides fuel to vital tissues, such as the heart, and lipids for storage in adipose tissue (Olivecrona and Olivecrona, 2009; Wang and Eckel, 2009) . Lipolysis also leads to the production of atherogenic remnant lipoproteins (e.g., low-density lipoproteins) and provides lipids for the formation of high-density lipoprotein particles. LPL is a homodimer, and its activity requires a protein cofactor, apolipoprotein (apo-) CII, which is carried within lipoproteins. A deficiency of LPL or apo-CII causes familial chylomicronemia, a severe form of hypertriglyceridemia (Brunzell and Deeb, 2001) .
The lipolysis of lipoproteins by LPL occurs at the surface of capillaries, mainly in skeletal muscle, heart, and adipose tissue (Havel and Kane, 2001 ; Olivecrona and Olivecrona, 2009; Wang and Eckel, 2009 ). Remarkably, however, LPL is not expressed by capillary endothelial cells. Instead, LPL is produced by the parenchymal cells, myocytes and adipocytes, and secreted into the surrounding interstitial spaces. From there, LPL finds its way into the lumen of capillaries. An earlier study suggested that the VLDL receptor (VLDLR) might be involved in the transport of LPL across capillaries (Obunike et al., 2001) , but the significance of that finding is uncertain because VLDLR deficiency does not lead to hypertriglyceridemia (Frykman et al., 1995) . No further progress has been made on this issue, and the mechanism for the entry of LPL into capillaries remains unknown.
Recently, Beigneux et al. (2007) identified a critical role for GPIHBP1 in lipolysis. GPIHBP1 is a glycosylphosphatidylinositol (GPI)-anchored glycoprotein of the lymphocyte antigen 6 (Ly6) family and is expressed in endothelial cells. Cell transfection studies revealed that GPIHBP1 binds LPL and that this binding could be blocked with heparin. Gpihbp1-deficient mice develop severe hypertriglyceridemia, even on a chow diet, with plasma triglyceride levels >3000 mg/dl. These findings prompted Beigneux et al. (2007) to speculate that GPIHBP1 could serve as a binding site for LPL in capillaries; however, the precise role of this molecule in lipolysis was not elucidated.
In this study, we examined the role of GPIHBP1 in proper localization of LPL within capillaries and tested whether GPIHBP1 is the critical molecule in shuttling LPL from the interstitial spaces to the lumenal surface of capillary endothelial cells.
RESULTS

GPIHBP1 Is Present on the Lumenal Face of Capillaries
Early immunohistochemical studies with a rabbit antiserum against mouse GPIHBP1 revealed that GPIHBP1 is found on capillaries of heart, skeletal muscle, and adipose tissue (Beigneux et al., 2007) . In this study, to determine if GPIHBP1 is present on the lumenal surface of capillaries, wild-type and Gpihbp1-deficient (Gpihbp1 À/À ) mice were given an intravenous injection of an Alexa 555-labeled GPIHBP1-specific monoclonal antibody (antibody 11A12) and an antibody against CD31 (an endothelial cell marker). Five minutes later, the mice were euthanized and their tissues were perfused extensively with PBS. In the adipose tissue of wild-type mice, antibody 11A12 binding was restricted to capillaries, colocalizing with antibodies to CD31. In the adipose tissue of Gpihbp1 À/À mice, CD31 was found in capillaries, but GPIHBP1 was absent ( Figure 1A ). Similarly, GPIHBP1 and CD31 colocalized in the capillaries of the heart in wild-type mice, but only CD31 was detected in Gpihbp1 À/À mice ( Figure 1B ). Interestingly, GPIHBP1 was confined to capillaries surrounding myocytes, whereas CD31 was found in both capillaries and larger vessels ( Figure 1B) . GPIHBP1 was not detectable in the capillaries of the brain ( Figure S1 ).
GPIHBP1 and LPL Normally Colocalize in Capillaries
Because expression of GPIHBP1 in Chinese hamster ovary (CHO) cells confers the ability to bind LPL (Beigneux et al., 2007 (Beigneux et al., , 2009a (Beigneux et al., , 2009b Gin et al., 2008) , we hypothesized that at least some of the LPL in mouse tissues might colocalize with GPIHBP1 in capillaries. To test this hypothesis, we performed immunohistochemistry with a chicken antibody against bovine LPL and a goat antibody against a recombinant mouse LPL fragment (Olivecrona and Bengtsson, 1983; Weinstein et al., 2008) . Both antibodies identified a single 52 kDa protein in CHO cells expressing V5-tagged mouse LPL (Figures S2A and S2B) . By immunofluorescence, both antibodies bound mouse LPL-transfected CHO cells ( Figure S2C ). When Lpltransfected and Gpihbp1-transfected CHO cells were mixed, immunofluorescence microscopy revealed that LPL and GPIHBP1 colocalized on the surface of cells (i.e., the LPL secreted by LPL-expressing cells bound avidly to Gpihbp1-transfected cells) ( Figure S2D ), showing that both antibodies Figure S1 . ) bind LPL when it is also bound to GPIHBP1. Both antibodies detected mouse LPL in the heart of wild-type mice, but neither detected LPL (human or mouse) in the hearts of Lpl À/À mice that had been rescued with a muscle-specific human Lpl transgene (Weinstock et al., 1997) (Figures S2E and S2F) . By immunofluorescence microscopy, most of the LPL in brown adipose tissue was located in capillary endothelial cells, colocalizing with GPIHBP1 (Figures 2A and 2B ). Both LPL and GPIHBP1 were identified in capillaries; neither was found in larger blood vessels ( Figure 2B ). The capillaries of the heart, all positive for GPIHBP1, also stained for LPL; this capillary staining was intense and was visible above the less-intense LPL staining in myocytes ( Figures S2E, S2F , and 2C).
LPL Is Mislocalized Away from Capillaries in Gpihbp1
À/À Mice To determine if GPIHBP1 plays a role in the targeting of LPL to capillaries, we examined the localization of LPL in the tissues of Gpihbp1 À/À mice. The LPL in brown adipose tissue of Gpihbp1 À/À mice surrounded adipocytes, colocalizing with the extracellular matrix protein collagen IV ( Figure 3A ). Similar mislocalization was observed in both heart and skeletal muscle of Gpihbp1 À/À mice; the LPL surrounded myocytes, colocalizing with b-dystroglycan (a plasma membrane protein of myocytes) ( Figures 3B, 3C , and S3A) or laminin, a basement membrane protein surrounding myocytes ( Figures S3B and S3C ).
GPIHBP1-Mediated Transport across Endothelial Cells
The mislocalization of LPL in Gpihbp1 À/À mice prompted us to consider the possibility that GPIHBP1 plays a role in the transport of LPL across capillary endothelial cells. We reasoned that the involvement of GPIHBP1 in transport would require that GPIHBP1 be present on the basolateral surface of cells (in proximity to the LPL secreted by adipocytes and myocytes). To determine if some GPIHBP1 is present on the basolateral surface of cells, we examined rat heart microvessel endothelial cells (RHMVECs) that expressed an S-protein-tagged version of GPIHBP1. We used RHMVECs that had been transduced with a mouse Gpihbp1 lentivirus because the expression of Gpihbp1 from the endogenous gene is nearly undetectable within a day after plating primary cells . We compared Gpihbp1 expression levels in transduced RHMVECs with Gpihbp1 expression levels in endothelial cells of mouse tissues by quantitative RT-PCR, normalizing the data to Cd31 (expressed only in endothelial cells). Gpihbp1 expression in lentivirus-transduced RHMVECs was $20% of endothelial cells in brown adipose tissue and $40% of endothelial cells in the heart ( Figure 4A ). The Gpihbp1-and empty vector-transduced RHMVECs were grown on polyethylene terephthalate filters (1 mm pore size), which make it possible to expose the basolateral surface of cells to one medium and the apical surface to another. The RHMVECs formed tight monolayers, as judged by electrical resistance measurements and the ability of the monolayer to prevent the flow of medium from one chamber to the other. To determine if GPIHBP1 is present at both the apical and basolateral surfaces of endothelial cells, phosphatidylinositol-specific phospholipase C (PIPLC) was added to the apical or the basolateral chamber, and the release of GPIHBP1 into the medium was monitored with western blots. PIPLC released GPIHBP1 from both the basolateral and apical surface of cells ( Figure 4B ). One possible explanation for the lower amount of GPIHBP1 release from the basolateral surface was that the access of PIPLC to the basolateral surface of cells may have been limited (pores represent only $4% of the surface area of the filters).
GPIHBP1 localization in endothelial cell monolayers was also examined by microscopy. For these experiments, Alexa 555-labeled antibody 11A12 was added to both the apical and basolateral chambers. By confocal microscopy, GPIHBP1 was detected in the uppermost and middle optical slices of endothelial cells. When the most inferior slices of the cells were examined, small patches of intense GPIHBP1 staining were observed, corresponding to regions of the plasma membrane adjacent to the filter's pores (i.e., the regions in direct contact with the antibody in the medium) ( Figure 4C ). To test whether GPIHBP1 could traverse endothelial cells, we measured its ability to transport a specific anti-GPIHBP1 monoclonal antibody (11A12) from the basolateral media to the apical media. RHMVECs were grown on filters ( Figure 4D ), and IRDye800-conjugated antibody 11A12 and an IRDye680-conjugated irrelevant antibody (a donkey antigoat IgG) were added to the basolateral chamber. After a 3 hr incubation at 37 C, the apical surface of the cells was incubated with PIPLC, releasing GPIHBP1 along with any bound antibody into the medium. The amount of each antibody in the apical medium was assessed by dot blot with an Odyssey infrared scanner. Neither the GPIHBP1-nor the vector-transduced cells transported the irrelevant antibody into the upper chamber efficiently, but the GPIHBP1-transduced cells transported antibody 11A12 into the upper chamber (Figures 4E and 4F) . The transport of antibody 11A12 required the presence of GPIHBP1 at the basolateral surface of cells; when basolateral GPIHBP1 was clipped off with PIPLC, transport of the antibody to the apical chamber was abolished ( Figure 4G ).
GPIHBP1 Transports LPL across Endothelial Cells
To test whether GPIHBP1 could transport LPL across endothelial cell monolayers, human LPL (hLPL) was added to the basolateral side of Gpihbp1-transduced RHMVECs. After a 1 hr incubation at 37 C, the LPL content of the apical medium was assessed by dot blot. In some studies, cells were treated with heparin to release any surface-bound LPL into the medium. Even in the absence of heparin, more LPL was present in the apical medium of Gpihbp1-transduced cells than in vectortransduced cells ( Figure 5A ). When heparin was added to release cell-surface LPL, the differences in the content of LPL in the apical medium were more pronounced ( Figure 5A ). In control experiments, we found that bovine serum albumin (BSA) transport was not affected by the expression of GPIHBP1 or by the addition of heparin to the apical surface of cells ( Figure S4A ). We also found that the amount of LPL transported to the apical surface of cells was dependent on the amount of LPL in the basolateral medium ( Figures S4B and S4C ). Finally, LPL transport occurred when Gpihbp1-transduced bovine aortic endothelial cells were used instead of RHMVECs ( Figures S4D and S4E ).
We also assessed transport of a highly purified bovine LPL preparation across Gpihbp1-and vector-transduced RHMVECs. Once again, LPL was placed in the basolateral medium; after 1 hr, heparin was added to the apical chamber, and the LPL concentration in the apical medium was measured with an ELISA. LPL transport to the apical surface of cells was absent in vector-transduced cells but was easily detectable with Gpihbp1-transduced cells ( Figure 5B ).
When the LPL transport studies were carried out at 4 C, GPIHBP1-specific transport of LPL was blocked ( Figure 5C ). At 37 C, adding heparin or PIPLC to the basolateral chamber largely blocked the transport of LPL ( Figure 5D ). Gin et al. (2008) showed that the acidic domain of GPIHBP1 is required for LPL binding. We predicted that a mutant GPIHBP1 lacking the acidic domain would be unable to transport LPL but would retain the ability to transport antibody 11A12 (which binds to an epitope outside of the acidic domain) (Beigneux et al., 2009b) . To test this prediction, we generated a mutant GPIHBP1 lentivirus in which all of the aspartates and glutamates in the acidic domain were replaced with alanine (D,E(24-48)A). Endothelial cells transduced with this mutant GPIHBP1 transported antibody 11A12 normally ( Figure 5E ), but their ability to transport LPL was markedly impaired ( Figure 5F ).
GPIHBP1 Can Function as a Transporter In Vivo
We sought evidence that GPIHBP1 was present on both the basolateral and apical (lumenal) surfaces of capillary endothelial cells in vivo and that it could function as a transporter. To assess the presence of GPIHBP1 on the apical and basolateral surfaces of capillary endothelial cells, we examined cross-sections of capillaries in brown adipose tissue by confocal microscopy. The basolateral and apical surfaces of endothelial cells could be easily resolved in crosssections of capillaries containing a cell nucleus. In those sections, GPIHBP1 was present on both the apical and basolateral surfaces. The amount of GPIHBP1 on the basolateral and apical surfaces of endothelial cells was roughly equivalent ( Figure 6A ).
To determine if GPIHBP1 could function as a transporter in vivo, we performed an intramuscular injection of one quadriceps muscle in wild-type and Gpihbp1 À/À mice with the GPIHBP1-specific monoclonal antibody 11A12, along with nonimmune rabbit IgG. After 30 min, the mice were injected intravenously with fluorescently labeled secondary antibodies, with the goal of ascertaining whether either antibody had been taken up by endothelial cells and transported into the lumen of capillaries. Three minutes after the intravenous injection of the fluorescent antibodies, the mice were extensively perfused with PBS, and tissues were fixed in situ with paraformaldehyde (PFA). Frozen sections were prepared and stained with an antibody against CD31 to identify endothelial cells. In wild-type mice, the fluorescent anti-rat antibody was detected exclusively in capillaries, colocalizing with CD31. No such (A) Gpihbp1 expression levels in lentivirus-transduced RHMVECs and mouse heart, skeletal muscle, brown adipose tissue (BAT), and white adipose tissue (WAT). Gpihbp1 expression levels were measured by quantitative RT-PCR and normalized to Cd31 (mean ±SEM).
(B) Release of GPIHBP1 by PIPLC from apical and basolateral surfaces of Gpihbp1-transduced RHMVEC monolayers grown on filters. After incubating the cells with PIPLC (5 U/ml) for 1.5 hr, the medium was harvested from the apical and basolateral chambers, precipitated with 10% TCA, and size fractionated by SDS-PAGE. Western blots were performed with antibody 11A12. (C) Confocal microscopy showing the binding of antibody 11A12 to Gpihbp1-transduced RHMVECs. Alexa 555-labeled antibody 11A12 was added to both the apical and basolateral chambers, and images of optical sections were obtained with a confocal microscope (633 objective) near the top, middle, and bottom of the cells. Green lines outline individual cells.
(D) Schematic of the transport assay. RHMVECs were grown on filters (1 mm pore size) until they formed a tight monolayer. Antibodies were added to the basolateral chamber and cells were incubated at 37 C. After the incubation, PIPLC was added to the apical chamber to release GPIHBP1; media from the apical and basolateral chambers were collected and analyzed.
(E and F) Dot blots demonstrating the transport of antibody 11A12 from the basolateral to the apical surface of Gpihbp1-transduced RHMVEC monolayers. IRDye800-labeled antibody 11A12 (green) and an IRDye680-labeled anti-goat IgG control antibody (red) were added to the basolateral chamber and incubated staining was observed in Gpihbp1 À/À mice ( Figure 6B ). The fluorescently labeled antibody against rabbit IgG was not detected in either wild-type or Gpihbp1 À/À capillaries ( Figure 6B ). Also, in the wild-type mice, no staining of capillaries was observed in the contralateral (noninjected) quadriceps muscle. As expected, when adjacent sections of skeletal muscle were directly stained with fluorescently labeled anti-rat and anti-rabbit secondary antibodies, we observed abundant amounts of antibody 11A12 and the rabbit IgG in the interstitial spaces (surrounding the myocytes of wild-type and Gpihbp1 À/À muscle) ( Figure 6C ).
for 3 hr at 37 C. The apical surface was treated with PIPLC (1 U/ml; 30 min) or PBS, and both apical and basolateral media were dot blotted, scanned, and quantified with the Odyssey scanner. Bar graph in (F) shows the fold change (mean ±SEM) compared to untreated vector-transduced cells from four independent experiments. (G) Analysis of the ability of basolateral PIPLC to block the transport of antibody 11A12 from the basolateral to the apical chamber. IRDye800-labeled antibody 11A12 and IRDye680-labeled anti-goat IgG antibody were added to the basolateral chamber in the presence or absence of PIPLC (1 U/ml) and incubated for 1.5 hr at 37 C. The apical surface was treated with PIPLC (1 U/ml; 30 min), and the apical medium was dot blotted, scanned, and quantified with the Odyssey scanner. The bar graph shows the fold change (mean ±SEM) compared to untreated vector-transduced cells. (A) Dot blot analysis demonstrating the transport of V5-tagged human LPL (hLPL) from the basolateral to the apical chamber by Gpihbp1-transduced RHMVECs. After adding LPL to the basolateral chamber and incubating for 1 hr at 37 C, either heparin (100 U/ml) or PBS was added to the apical chamber, and the apical medium was dot blotted with an antibody against the V5 tag and quantified with the Odyssey scanner. Bar graph shows the fold change (mean ±SEM) compared to vector-transduced cells from four independent experiments. (B) Transport of bovine LPL from the basolateral to the apical chamber by Gpihbp1-or vector-transduced RHMVECs grown on filters. After adding bovine LPL to the basolateral chamber and incubating for 1 hr at 37 C, the apical surface of cells was treated with heparin (100 U/ml) or PBS for 15 min at room temperature. The apical medium was collected, and the LPL concentration was determined with an ELISA. The bar graph shows the percentage of total LPL detected in the apical media (mean ±SEM). No LPL was detected in the samples marked n.d. (C) GPIHBP1-mediated LPL transport across endothelial cells at 4 C and 37 C. After adding V5-tagged hLPL to the basolateral chamber, Gpihbp1-transduced RHMVECs were incubated for 1 hr at 4 C or 37 C. Heparin was then added to the apical chamber (100 U/ml; 15 min at 4 C), and the amount of LPL in the apical medium was assessed by dot blot with an antibody against the V5 tag. The blot was scanned and quantified with the Odyssey scanner. Bar graph shows the fold change (mean ±SEM) compared to vectortransduced cells incubated at 37 C.
(D) Ability of PIPLC or heparin in the basolateral medium to block GPIHBP1-mediated transport of the V5-tagged hLPL from the basolateral to the apical medium of RHMVECs. After adding LPL and either heparin (100 U/ml) or PIPLC (2.5 U/ml) to the basolateral chamber, the cells were incubated for 1 hr at 37 C. Heparin was added to the apical chamber (100 U/ml; 15 min at room temperature), and the amount of LPL in the apical medium was then assessed by dot blotting with an antibody against the V5 tag. The blot was scanned and quantified with the Odyssey scanner. Bar graph shows the fold change (mean ±SEM) compared to vector-transduced cells. (E) Dot blot analysis of antibody 11A12 transport in RHMVECs transduced with wild-type or mutant (D,E(24-48)A) GPIHBP1. IRDye800-labeled antibody 11A12 was added to the basolateral chamber and incubated for 1 hr at 37 C. The apical surface was then treated with PIPLC (1 U/ml; 30 min) or PBS; the apical medium was dot blotted, scanned, and analyzed with the Odyssey scanner. Bar graph shows fold change (mean ±SEM) compared to vector-transduced control cells. (F) Dot blot analysis of LPL transport in RHMVECs transduced with either wild-type or mutant (D,E(24-48)A) GPIHBP1. After adding LPL to the basolateral chamber and incubating for 1 hr at 37 C, the apical surface was treated with PIPLC (2.5 U/ml) or PBS (30 min at 37 C). The apical medium was then dot blotted with an antibody against the V5 tag, and the signal was quantified with the Odyssey scanner. Bar graph shows the fold change (mean ±SEM) compared to vectortransduced control cells. (See also Figure S4 .)
Absence of LPL at the Lumenal Surface of Capillaries in Gpihbp1 À/À Mice
The fact that GPHBP1 functions as a transporter in vivo combined with the fact that LPL is mislocalized in Gpihbp1 À/À mice made us suspect that LPL would be absent from the lumenal surface of capillaries of Gpihbp1 À/À mice. To address this issue in a direct fashion, wild-type and Gpihbp1 À/À mice were injected intravenously with an anti-LPL antibody as well as FITC-labeled tomato lectin (which binds to the lumenal surface of capillaries). Five minutes later, mice were euthanized, their tissues were extensively perfused with PBS, and the heart was harvested. In the heart of wild-type mice, LPL was visible within capillaries, but LPL was nearly undetectable in the capillaries of Gpihbp1 À/À mice ( Figure 7A ).
We also examined LPL localization in Gpihbp1 À/À mice with confocal microscopy of cross-sections of capillaries in brown adipose tissue of wild-type and Gpihbp1 À/À mice. As expected, GPIHBP1 was present on both the lumenal and ablumenal surfaces of endothelial cells in wild-type mice ( Figure 7B ). Of note, LPL was present on both the lumenal and ablumenal surfaces of capillaries in wild-type mice, but was absent from the lumen in Gpihbp1 À/À mice ( Figures 7B  and S5 ). These findings are consistent with the ability of GPIHBP1 to serve as a transporter from the basolateral to the apical surfaces of endothelial cells (Figures 4-6) and strongly support the idea that GPIHBP1 is the critical molecule for shuttling LPL from the interstitial spaces into the capillary lumen. 
DISCUSSION
That LPL is synthesized by adipocytes and myocytes but hydrolyzes triglycerides of lipoproteins within capillaries has been known for decades (Cryer et al., 1976; Havel and Kane, 2001 ). Precisely how LPL finds its way into capillaries, however, has been a mystery. In the current study, we provide evidence that GPIHBP1 is essential for LPL entry into capillaries. First, we found that LPL is mislocalized away from capillaries in the absence of GPIHBP1. GPIHBP1 is expressed exclusively in capillary endothelial cells, and in tissue sections of wild-type mice, most of the LPL colocalizes with GPIHBP1. In Gpihbp1 À/À mice, most of the LPL is found on the outside of parenchymal cells, colocalizing with collagen IV (in the case of brown adipose tissue) or b-dystroglycan or laminin (in the case of skeletal muscle and heart tissue). Second, we found that GPIHBP1 is present on both the basolateral and the apical surfaces of endothelial cells, both in cultured cells and in vivo within the capillaries of brown adipose tissue. Third, we show that the expression of GPIHBP1 in endothelial cells confers the ability to transport LPL and a GPIHBP1-specific monoclonal antibody from the basolateral to the apical surface of cells. This transport could be blocked by adding PIPLC to the basolateral chamber (an intervention that releases GPIHBP1 from the surface of cells). Also, the transport of LPL, but not the transport of antibody 11A12, was blocked by mutating the long stretch of negatively charged amino acids within GPIHBP1's acidic domain. Mutating the acidic domain eliminates the ability of GPIHBP1 to bind LPL but has no effect on the epitope for antibody 11A12 (Beigneux et al., 2009b) . Fourth, we show that GPIHBP1 transports a GPIHBP1-specific monoclonal antibody across endothelial cells in vivo. Finally, we show that LPL is absent from the capillary lumen in Gpihbp1 À/À mice. All of these findings point to a direct role for GPIHBP1 in transporting LPL from the interstitial spaces to the lumen of capillaries.
Our current studies explain enigmatic findings from earlier studies. First, the striking phenotype of Gpihbp1 À/À mice, severe hypertriglyceridemia (Beigneux et al., 2007) , which was initially puzzling, can now be more clearly understood. With little or no mouse. Images were taken with a 1003 objective without optical zoom or with 43 optical zoom. To visualize both the apical and basolateral surfaces of capillaries, cross-sections of capillaries that cut through an endothelial cell nucleus (blue) were identified (boxed areas) and viewed at high magnification. GPIHBP1 (purple), LPL (red), and CD31 (green) were all expressed at the apical and basolateral surfaces of endothelial cells in wild-type mice, but no LPL was present on the apical (lumenal) surface of the capillary endothelium in Gpihbp1 À/À mice. The scale bar represents a distance of 2.5 mm. (See also Figure S5 .)
LPL inside the capillaries of Gpihbp1 À/À mice, lipolytic processing of triglyceride-rich lipoproteins cannot occur. Second, our findings help to explain the abnormal kinetics of LPL release in Gpihbp1 À/À mice after an injection of heparin. Weinstein et al. (2008) found that the release of LPL into the plasma of Gpihbp1 À/À mice is delayed after a bolus of heparin, while LPL release is rapid in wild-type mice. In the current studies, we showed that LPL in Gpihbp1 À/À mice is located in close proximity to parenchymal cells, whereas it is largely associated with capillaries in wild-type mice. When LPL is located in capillaries, it makes sense that an intravenous bolus of heparin would release LPL quickly. In the case of Gpihbp1 À/À mice, it presumably takes longer for the heparin to reach the interstitial spaces and release that pool of LPL. Third, our findings provide an explanation for the normal LPL mass and activity measurements in Gpihbp1 À/À mice. By immunohistochemistry, we found substantial amounts of LPL in the tissues of Gpihbp1 À/À mice, but it was strikingly mislocalized. Very recently, mutations in GPIHBP1 have been identified in humans with severe hypertriglyceridemia (Beigneux et al., 2009a; Franssen et al., 2010; Olivecrona et al., 2010; Wang and Hegele, 2007) . All are missense mutations involving highly conserved amino acid residues within GPIHBP1's Ly6 domain. Functional studies on the mutant proteins have revealed that the mutations result in a loss of GPIHBP1's capacity to bind LPL.
The exact mechanism by which GPIHBP1 transports LPL across endothelial cells is not clear. Given the known association of GPI-anchored proteins with caveolae (Brown and Rose, 1992; Nosjean et al., 1997; Rajendran and Simons, 2005; Varma and Mayor, 1998) and the abundance of caveolae in endothelial cells (Anderson, 1993) , one possibility is that LPL is transported by caveolar-dependent transcytosis. This possibility needs to be investigated thoroughly.
Our immunochemical studies of GPIHBP1 were made possible by a new monoclonal antibody against mouse GPIHBP1, 11A12 (Beigneux et al., 2009b) . Antibody 11A12 binds avidly to GPIHBP1 in conventional immunohistochemistry studies and when injected intravenously into mice; these experiments revealed that GPIHBP1 is restricted to capillary endothelial cells and is absent in larger vessels. Our studies of LPL localization were aided by two antibodies against LPL, one generated against native bovine LPL and the other against a recombinant mouse LPL fragment; both antibodies were specific for LPL as judged by western blots and immunohistochemical studies with Lpl knockout mice. Both antibodies worked well in immunohistochemical studies, detecting LPL in parenchymal cells and in capillary endothelial cells (but not larger vessels), colocalizing with GPIHBP1. The availability of these antibodies provides for new approaches to investigate mislocalization of LPL away from capillaries as a potential explanation for hypertriglyceridemia.
The ability to visualize GPIHBP1 and LPL on the lumenal surface of capillaries and the ability to assess transport from the interstitial space to the capillary could open the door to a better understanding of hypertriglyceridemia. For many years, scientists interested in hypertriglyceridemia have focused on measuring LPL levels 15 min after an injection of heparin, LPL levels in tissue extracts, and LPL mRNA levels. Unfortunately, there is little reason to believe that these measurements provide an accurate representation of the amount of LPL in capillaries. Indeed, in the case of Gpihbp1 À/À mice, none of those measurements provided insights into the mechanism of hyperlipidemia. The phenotype of Gpihbp1 À/À mice only made sense with the realization that GPIHBP1 functions as a transporter and that no LPL is present in the lumens of capillaries of those mice. We speculate that assessing intracapillary LPL levels could prove to be worthwhile in other forms of hypertriglyceridemia, aside from those caused by specific structural abnormalities in GPIHBP1.
In humans, mechanisms for severe cases of hypercholesterolemia have come into focus (Goldstein et al., 1985 (Goldstein et al., , 2001 Horton et al., 2009 ), but the same cannot be said for many cases of severe hypertriglyceridemia. Many patients with severe hypertriglyceridemia have no mutations in LPL, GPIHBP1, APOCII, or APOAV and no obvious explanation for their disease (Beigneux et al., 2009a; Wang and Hegele, 2007) . For some patients with hypertriglyceridemia, there are no obvious abnormalities in tissue stores of LPL or levels of LPL in the postheparin plasma-a situation reminiscent of Gpihbp1 À/À mice. Thus, it seems possible that defective transport of LPL into the lumen of capillaries could underlie at least some cases of hypertriglyceridemia in humans. A structurally intact GPIHBP1 is a cornerstone of this transport, but we suspect that other proteins participate in this process. Elucidating those factors might represent a productive area for future research.
EXPERIMENTAL PROCEDURES Mice
Gpihbp1
À/À and L0-MCK mice (Lpl-deficient mice expressing hLPL from a muscle-specific promoter [MCK]) have been described previously (Beigneux et al., 2007; Weinstock et al., 1997) . Mice were fed a chow diet and housed in a barrier facility with a 12 hr light-dark cycle. All studies were approved by UCLA's Animal Research Committee.
Antibodies, Immunohistochemistry, and Antibody Injection Experiments A rat monoclonal antibody against mouse GPIHBP1 (11A12) has been described previously (Beigneux et al., 2009b) . In some experiments, antibody 11A12 was coupled to fluorescent dye Alexa 555 (Invitrogen; Carlsbad, CA) or infrared dye IR800 (LI-COR; Lincoln, NE). We also used a chicken antibody against bovine LPL (Olivecrona and Bengtsson, 1983 ) and a goat antibody against a recombinant mouse LPL fragment produced in Escherichia coli . The specificity of the LPL-specific antibodies was assessed by western blot and by immunocytochemistry (see Supplemental Experimental Procedures). To detect GPIHBP1 in mouse tissues, 8-10 mm-thick frozen sections were prepared and incubated with primary antibodies (3 mg/ml for monoclonal antibody 11A12, 1:400 for the hamster anti-CD31 antibody [Millipore; Billerica, MA], 1:200 for the rabbit anti-b-dystroglycan antibody [Santa Cruz Biotechnology; Santa Cruz, CA], 1:1000 for the rabbit anti-collagen type IV antibody [Cosmo Bio USA; Carlsbad, CA], 1:160 for the rabbit anti-laminin antibody [Millipore] , 7 mg/ml for the chicken anti-bovine LPL antibody, and 10 mg/ml for the goat anti-mouse LPL antibody). Secondary antibodies (Alexa 555-or Alexa 649-labeled anti-rat IgG, Alexa 488-or Alexa 649-labeled anti-hamster IgG, Alexa 488-or Alexa 649-labeled anti-rabbit IgG, Alexa 546-labeled antichicken IgG, and Alexa 549-or Alexa 488-labeled anti-goat IgG) were used at a dilution of 1:200 and were incubated with slides at room temperature (RT) for 1 hr. Images were obtained with an Axiovert 200 MOT microscope equipped with an Apotome (both from Zeiss; Oberkochen, Germany) or by confocal fluorescence microscopy with a Leica SP2 1P-FCS microscope (Heidelberg, Germany) as described in the Supplemental Experimental Procedures.
In some experiments, mice were injected intravenously with 50 mg GPIHBP1-or 200 mg LPL-specific antibodies in a volume of 0.1 ml. After 3 min, mice were perfused with 10 ml PBS (2-3 ml/min) through the left ventricle followed by 10 ml of 3% PFA in PBS. The tissues were embedded in optimal cutting temperature (OCT) compound and processed for immunohistochemistry.
For in vivo antibody transport experiments, one quadriceps muscle of wildtype and Gpihbp1 À/À mice was injected intramuscularly with 10 ml normal saline containing 15 mg each of the rat anti-GPIHBP1 antibody 11A12 and nonimmune rabbit IgG. After 30 min, the mice were injected intravenously with 200 mg each of Alexa 488-labeled goat anti-rabbit IgG and Alexa 568-labeled goat anti-rat IgG. Three minutes later, the mice were perfused with PBS and tissues were fixed in situ with 3% PFA. The tissues were embedded in OCT and processed for immunohistochemistry.
Production of GPIHBP1-Expressing Endothelial Cell Lines
RHMVECs and bovine aortic endothelial cells were obtained from VEC Technologies (Rensselaer, NY) and grown in MCDB-131 complete medium with antibiotics. The coding sequences for an S-protein-tagged GPIHBP1 (Beigneux et al., 2007) were cloned into the lentiviral vector pRRL-cPPT-MCS-IRES as described in the Supplemental Experimental Procedures. A lentivirus for an S-protein-tagged mouse GPIHBP1 mutant (D,E(24-48)A) in which all of the aspartates and glutamates between residues 24 and 48 were replaced with alanine (EDGDADPEPENYNYDDDDDEEEEEE to AAGAAA PAPANYNYAAAAAAAAAAA) was created by site-directed mutagenesis with Phusion mutagenesis (Finnzymes; Espoo, Finland).
To assess levels of Gpihbp1 expression, total RNA was prepared from mouse tissues with TRI Reagent (Sigma; St. Louis) and from transduced cells with the RNeasy Kit (QIAGEN; Valencia, CA). RNA was treated with DNase I (Ambion; Austin, TX) and reverse transcribed into cDNA with a mixture of random primers, oligo(dT), and SuperScript III (Invitrogen). Primers 5 0 -AG-CAGGGACAGAGCACCTCT-3 0 and 5 0 -AGACGAGCGTGATGCAGAAG-3 0 were used to amplify the mouse Gpihbp1 cDNA, and primers 5 0 -CAGCGAGAT CCTGAGGGTCA-3 0 and 5 0 -TCCCCTCTTTCACAGAGCACC-3 0 were used to amplify mouse and rat Cd31 cDNAs. PCR reactions were performed in triplicate on a 7900HT Fast Real-Time PCR system (Applied Biosystems; Foster City, CA). Gene expression levels were calculated with the comparative cycle threshold (C T ) method.
Production of LPL for LPL Transport Assays hLPL was concentrated from the medium of a CHO cell line stably expressing V5-tagged hLPL (a gift from Mark Doolittle, UCLA) (Beigneux et al., 2009b) . The production of bovine LPL is described in the Supplemental Experimental Procedures.
Endothelial Cell-Based Assays of LPL Transport Endothelial cells were grown on Millicell filters (polyethylene terephthalate, 1.1 cm 2 filtration area, 1 mm pore size; Millipore) that had been coated with fibronectin (BD Biosciences; San Jose, CA). Cells were grown until they formed tight monolayers as judged by electrical resistance (tested with a Millicell Electrical Resistance System; Millipore) or by observing water tightness over 24 hr. For each assay, monolayers were monitored for leakage by observing the transport of either an irrelevant antibody (IRDye680-labeled donkey anti-goat IgG; LI-COR) or BSA (1 mg/ml; Amresco; Solon, OH). For antibody transport assays, IRDye800-labeled antibody 11A12 and an IRDye680-labeled donkey anti-goat IgG antibody (LI-COR) were added to the bottom (basolateral) chamber in PBS at a concentration of 0.25 mg/ml. After incubating the cells for the specified times at 37 C, 1 U/ml of PIPLC was added to the apical chamber to release GPIHBP1. Antibody in apical and basolateral media was detected by dot blotting or western blots (Supplemental Experimental Procedures). For LPL transport assays, human or bovine LPL (hLPL or bLPL, respectively) was added to the basolateral chamber and PBS was added to the apical chamber. Cells were incubated at 37 C for 1 hr and treated with either heparin (100 U/ml for 15 min at RT; APP Pharmaceuticals; Schaumburg, IL) or PIPLC (2.5 U/ml for 30 min at 37 C) to release LPL from the cell surface. Apical and basolateral samples were then collected, and relative amounts of LPL were assessed by dot blotting, western blots, or an ELISA (Supplemental Experimental Procedures).
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